We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » FDA Approves First-in-Class Antibody-Drug Conjugate for Diffuse Large B-cell Lymphoma
FDA Approves First-in-Class Antibody-Drug Conjugate for Diffuse Large B-cell Lymphoma
Genentech has won full approval for its first-in-class combination therapy aimed at providing curative treatment for patients with previously untreated diffuse large B-cell lymphoma (DLBCL), the most common form of non-Hodgkin lymphoma in the U.S.